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Oncology 
Options for Breast Cancer Prevention in High-Risk Patients 
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Abstract 
Breas· ca ~r IS the most lreque111y diagnosed non-skin caocer rn 
women. arxl one in e ghl Yromen will develop breasl caocerwi!hin Ifie r 
b.fellmes. Unfortunate y, the strongesl nsk factors for breast cancer (i.e. 
age, family history, hormonal lac1ors) are no1 eastly rnodlheo. There 
is some evdence 1hat chemofl"evan11ve drugs may be able to prevent 
breast cancer 1n h1gh-nsk patients. Tamox1fen and raloxifene have been 
shown to reduce Iha nsk of breast cancer 1n h1gh-nsk women but may be 
associated with several senous adverse evenls Clinical tnals are current 
ly 1n p<ogress 10 de1enn1ne 11 aromalase mh1b1tors are a viable allematrve 
for b<east cancer p<evenuon, as they may be considered effecuve in 1he 
early treatmenl of breast cancer For J:lllients with BRCAt and BRC/.2 
mu1a1ions. a bilateral prophylachc mas1ectomy may be an option. This 
artcle discusses the nsks and beneflls of available trea1ment opt10ris for 
breas1 cancer J:IOV91'lll0tl in hlgh·llSk patients. 
Introduction 
Breast cancer s Ille most frequen:ly diagnosed non-skin cancer tn 
women arxl me second most com110n cause of cancer death ui women. 1 
One n eighl women will develOp tt1eas1 cancer w;lhm their !lfellmeS 2 
Some breast cancers are esuogen-Oependent for growtil and are l<OOwn 
as esuogen recepror pos ttve (ER·JX>Slllve) breast cancers. oiher oceasr 
cancers are considered estrogen recepror negattve (ER-negalJVe 1 and 
comixise<l or cers witnout esuogen receptors 1 The presence or these 
receptors IS an llTIJX>rtant part of 1een1Jfymg useful treatmenr opoons • 
Unfortunately. the s1ronges1 nsk fac1ors for breast cancer (1.e age ram-
lly h1Story, hormonal factors) are not easily modified In high-nsk patienis, 
muraoons 1n BRCA 1 BRCA2 greatly increase lifetime nsk of cancer.5 
Prophylactc masl9Cromies for BRCA t and BRCA2 mutatt0n earners are a 
growing trend m breast cancer prevention However, since not all women 
with these muta1t0ns will develop breast cancer, those consldenng thlS 
alternaove should receive counselmg on ell available options before making 
a final decis10n •Thus, other preventive strategies must be considered. 
There IS some evidence lhal chemoprevenbve drugs may be able to 
prevem breas1 cancer Currently, chemopravention may be considered tor 
patJents a1 a high nsk for developmg breast cancer based UJX>n family h1S-
tory, as the benefns do no1 outweg1 the nsks for routine use in all patients.' 
Tamoxifen 
meas.ires.:.io Oesp;:e l1l9 possible side effects, the use o' iamOxlfer> as a 
pmphylactx: measure IS supported by two lo~rm slUdJeS. wtoch ron-
ctuded these side effecis do not persist, while tile benefits do.9•11 
The Royal Marsden Tnal included 2.471 women bet'Ween 30 and 70 
years of age with a family h1Story of breast cancer who were randomrzed 
to rake either tamoxtfen or placelxl for eight years. Results did not show 
an overall reducoon in breast cancer evenlS be:ween the tamoxifen and 
placelxl groups (p..0.2). However, following the eight-year acllve phase, the 
women participated In six-month follow-ups, and a blinded follow-up srudy 
was performed 20 years later {median follow-up 13 years) to d910rmine 
whether tamox1ten provided 1ong-te1m benefits to overall breast cancer and, 
spectooally. with ER-positive breast cancers. Overall, 209 b<east cancer 
cases, 1nclud1ng 186 invasive cases, were documented with no differences 
noted between tamox1len and placelxl groups (p..O 2). Of the 111Vasive breast 
cancer cases. the estrogen receptor status was ava1labl9 for 180. Of these, 
139 were ER-JX>smve, with 53 occumng in the ~moxlfen group and 86 oc-
currmg :n the placelxl group. ResutlS showed that the iamox!fen group had a 
39 percent lower incidence of mvaslV9 ER-posr.ive breast carx:ers versus the 
placelxl group (p,.().005). The adverse even: pm"'es tor lxllh arms occurred 
pmdominantJy dunng the O'llatment perod, wo:hgynecolog£ :Oxi:iiy OOIOQ 
!he most chmcally 1mJX>rtant There was no evcence o' any increase in the 
ll'IOOenoe of non-breast arxl non-endomeinal cancers. rus study suggesrs 
ramoxr.en provides long-term nsk reducoon forER-posltlVe treastcaooer• 
The n:emaoonal Bteast Cancer lnrervenoon Stooy 1Bl8-i was a 'ive-year 
double b"nd randomlZed ll181companng1amox~n to placebo in women Wllll 
an ocreased nsk for breast cancer. 11 Tt19 results of ttus study whd1 rcluded a 
total or 7 154 women, found a statJSIJCa!ly sgmfK:ant decrease r1 the incidence 
or ER·P>s111va breast cancer 1n the ramoxtfen grcup (p,.Q.O 13) Regarding side 
effects, a sgmf1cant increase 1n endometnal cancer was found in the 1amoxrren 
group dunng the active period (P=0.02), but lollow1ng the acove peood, the d1f· 
ference was not s1gn1f1cent (p .. 0.2). The tamox1fen group also had a significant 
111Crease in thromlxlemlxlltc events (p .. 0.001) as well as deathS (p:0.028), 
but no spec1f1c cause of death was s1gmficant The 96-month follow-up of this 
study also demonstrated the err1cacy of tamox1len for the prevention of breast 
cancer, reP>itmg the development of 337 total bteastcancercases with a 27 
percent lower incidence rate with tamox1fen than placelxl (p:0.004). Overall, 
a 32 percent reduct10n m breast cancer was seen 1n years zero to four, and 44 
percent thereafter no reduct10n was seen 1n ER-oegallve breast cancer. The 
nsk reducoon was found to be greater for premeoopausal women, who also 
had a lower number of endometnal cancer cases and ihromlxlemlxl!K: events. 
Therefore, these teSullS support the use of ramoitfen as chemopreventnn in 
J,Yemenopausal women ThlS follow-up srudy suPJX>ns kl~rm oonefils of ta-
moxlfen for ER·pos1!JV9 breast cancer nsk reoUC110n wh\9 showing the adverse 
e"ects are urekey to perstSt Jl!Sl the treatment phase 
Tamoxifen a seleeove estrogen receixor modulator (SERM was air 
proved by the Food and Drug Adm n1Straoon (FDA) m the late 1990s for 
breast cancer chemop-evenoon By compebovely 0tnd1ng estrogen recep-
iors 1n breast llSSue. deereasing DtJA syntheslS end inh1tl1lllJ es:mgen 
e~eciS, ramoxJen IS shown to redu:e the nsk of breast cancer t1f oo-50 
pertem lt'I hgh-nsk VtOmen 11 In contrast estrogen recep!Drs Ill the u:erus Raloxilene 
are sllmulated rather tnen lt'lh a:ed by ramox1fen. Estrogenc erects 11 1t1e Ra bx Jene IS a seleewe estrogen recepeor modulalDr SERM that com-
uterus 1ncr13ase the nsk of endome1181 cancer Paoenis taking tamoxlfen peonvery antagonizes estrogen-induced ONA trallSCJ 1poon of estrogen on 
am also at mcreased nsl< of lhromboemlxlhc events. These nsks require receptors lfl breast and utenne t1Ssues •:It a ISO acts as an estrogen agon1St 
1amox1mn ID carry blaelc box warnings for ut13nne mahgnancies. s1ro!ce 11 lxlne therefore 1ncraas1ng lxlne density Labeled lndcaoons for ralox· 
and pulmonary emlxll1Sm which hn11 the use of thlS drug for propf1ylact£ k'ene include preventt0n and treatment of osteopOrostS m p.:ist-menopausal 
women as well as the prevent10n of breast cancer ui tugh-nsk patients. tJ 
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The clinical effectJveness of ra loxifene is evident in two prominent 
trials. The Mulnple Outcomes of Raloxifene Evaluation (MORE) is a 
mutucenter, double-blind, randomized 1rial comprised of 7 ,705 women 
who were followed from 1994 to 1998.12The primary outcome of the 
trial was osteoporosJS preventJon, with breast cancer prevention as a 
secondary end point Raloxifene reduced the nsk of invasive ER-pos1irve 
breast cancer by 00 percent but did not have a stallstically significant 
effect on invasive ER-negative breast cancer. The overall risk of invasive 
breast cancer was reduced by 76 percent. Ills also important to note 
that raloxifene did not increase the risk of endometrial cancer in the 
study patients. The Continuing Outcomes Relevant to Evista (CORE) 
trial is a continuation of the MORE trial, where patients' raloxifene treat-
ment was continued for four additional years in order to study long-term 
effects of therapy. 14Women who agreed to continue in the study {n= 
4,01 1 patients) were either continued on placebo therapy or assigned 
to raloxifene tf they received acnve treatment m the previous trial. The 
women who received ralox1fene had a 59 percent reduced incidence of 
invasive breast cancer compared ro the placebo group. This included 
a 76 percent reduction 1n ER-pos11ive 1nvas1ve breast cancer and no 
stat1st1cally significant reduction 1n ER-negative 1nvas1ve breast cancer. It 
could not be determined whether 1he reduction was a result of 1he 1n11lal 
four-year therapy or the continuation of treatment in the CORE trial. 
The adverse evenlS from ralox1tene treatment were s1m1lar for both the 
MORE and CORE tnals. 12•14 Reported events included hot Hashes, deep 
vein thrombosis, retinal vem thrombosis, leg cramps, myocardial infarc-
tion, stroke, cataracts, ovarian cancer and breast pain. However. none 
of the events were statlS!lcaUy sign'ficant m the treatment group versus 
the placebo group. A higher incidence of pulmonary embolism occurred 
in the raloxifene group compared to placebo for the eight-year period of 
treatment Although the increased risk of thromboembolic disease was not 
overall statistically significant in the treatment group versus placebo, the 
researchers did note that raloxifene should be used with caution 1n pallents 
who are already at an increased nsk ot t11rombOembOl1c events. 
The Nanonal Surgical Ad11vant Breast and Bowel Pro pct {NSABP) 
Study ofTamox1fen and Raloxifene (STAR) mal was conducted as a 
fo llow-up to the Breast cancer Prevention Tnal (BCPT). which studied the 
effecr1veness of tamox1fen for preventing breast cancer. '5To obtain FDA 
approval of ra10x1fene as a preventative tl1erapy for patients at h1gh-rJSk for 
breast cancer, researchers compared tamoxifen to raloxifene. The STAR 
trial was a prospecllve, double-blind, randomized, phase-Il l tnal conducted 
from July 1, 1999, to Dec. 31, 2005. Within that time penod, therapy was 
uterine hyperplasia and hysterectomy events When compared to tamox-
1fen. Overall, ra loxifene has a decreased effecron adverse events associ-
ated with utenne tissue, Raloxifene patients had significantly fewer cases 
of deep vein thrombosis and pulmonary embolism. This result is significant 
for those patients who have an already Increased risk of thromboembolic 
event pnor to SERM treatment. 
In conjunction with the STAR tnal, the Patient-Reported Symptoms 
and Quality of Life During Treatment With Tamoxifen or Raloxifene for 
Breast Cancer Prevention trial captured the effects of SERM treatment 
on patients included in the trial. 16 The report concluded no significant 
difference between treatment groups tor overall physical and mental 
health. Raloxifene patients did experience a significant decrease in 
sexual interest (p= 0.009) and expenenced fewer musculoskeletal 
problems, such as leg cramps {P= 0.002). Tamoxiten patients experi-
enced significantly more vasomotor symptoms (p«l.001). Both treat-
ment groups experienced adverse events related to bladder problems 
(p«l.001 ), gynecological problems (p«l.001) and leg cramps (p«l.001 ). 
This report 1s a useful tool to evaluate quahty·of-hfe outcomes for two 
treatment methods with similar pharmacological outcomes. 16 
Ac the conclusJOn of the STAR tnal, the researchers noted some 
shortcomings of the study. 16 Although attempts were made to represent 
racial and ethnic groups within the populallOn of North America, the tnal 
did not meet the goal of proportlonal representation of the populaaon. 
ThlS is significant In evalualmg the treatment of patient populations who 
may not have been adequately represented within the tnal. The STAR 
trial was also unable to evaluate the adequate length ot SERM treat-
ment needed to prevent invasive breast cancer. '5 The Ina.I did provide 
necessary data to show that eight years of treatment reduced the 
incidence of invasive breast cancer, but decreased adverse effects could 
be achieved with a shorter treatment. The researchers noted that lack of 
information on treatment duration should not deter treatment, as long-
term studies have shown that tamoxiten is safe and effective 25 years 
alter tile drug was t1rst approved tor prevenoon. Whether or not one 
SERM was preferred over another was not concluded within the ST AR 
trial, however, ra lox1fene was FDA-approved for preventallve treatment 
of breast cancer. '5•11 Researchers believed that physJCians may be 
more likely to convert to raloxifene treatment for breast cancer preven-
aon since ralox1fene therapy exhibited decreased adverse events m the 
STAR tnal. Currently, neither SERM 1s recommended over another m 
prevention of invasive breast cancer guidelines. 
given tor five years with a one-year follow-up. Eligible participants included Aromatase inhibitors 
women who were required to have a five-year predicted breast cancer risk While tamoxiten and raloxifene are the medications conventionally used for 
of at least 1.66 percent based on the Gail Model, postmenopausal, and breast cancer prevention, aromatase inhibitors are an emerging option. 16 
not currently receiving tamoxifen or raloxifene therapy. At baseline, 19,7 47 Aromatase converts androgens to estrogen in the adrenal glands and other 
women were enrolled into treatment with a mean age of 58.5 years and a tissues: however, this is a minor estrogen synthesis pathway in premeno-
mean five-year predicted breast cancer risk of 4.03 percent. Patients were pausal women, who synthesize estrogen mainly in the ovaoos. For this 
randomized to receive tamoxiten or raloxifene and were stratified by age reason, aromatase inhibitors have little effect on estrogen synthesis in pre-
and race. Outcome comparison between treatment groups was based on menopausal women. Conversely, aromatase 1s lhe mam estrogen pathway 
determined rates of incidence per 1,000. in JX)Stmenopausal women, so aromatase inhibitors are reserved tor use in 
At the conclusJOn of the STAR trial, there was no sta tistically significant this population.19 Tl1ree aromatase inhibitors are currently available anastro-
d1fference between i:amoxiten (4.3 oer 1,000) and ra loxifene (4.41 per zole, letrozole and exemestane. 13 All three are 1n:ticated for the treatment of 
1,000) 1n preventing invasive breast cancer. 15 The result was not staustr early to advanced ER-pos1hve breast cancer, and all three drugs suppress 
cally stgnificant, although a difference was noted in prevention of non-mva- almost all estrogen production in postmenopausal women.11•1' 
s1ve breast cancer, spec1fically. fewer patients 1n the tamox1ten group {1.51 W1th1n the MORE tnal, it was hypothesized that 1nh1bitJOn of aromatase is 
per 1,000) developed non-invasive breast cancer than the raloxifene group at least equally effective 10 raloxlfene in breast cancer prevenoon, whch 1n111-
(2.11 per 1,000). There are multiple secondary endpoints to be considered ated the turtl1er research of all three aromatase inhibitors for FDA approval 
in the STAR tnal Within the raloxrfene group. there was a trend towards a as preV9ntative treatment of breast cancer 12,20 Currently, letrozole and 
decreased 1ncKlence of uterine cancer, although the result was not statlSll- exemestane are in phase-Il l trials and include postmenopausal women with 
cally significant Raloxifene did show a statistically significant reduction m 
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no p<ior history of breast cancer. Lelrozole and exemestane Dials are set to 
te completed w1th1n the next five years.2'.22 However, anastrozole research 
is soll 1n the recrumrg phase with no estimated conclusion date.zi 
The role of aromatase inhibttors 11 preventing breast cancer has yet tote 
shown. Because aromatase mhiblto-s are known tote successful for early 
breast cancer treatment, It IS possible that aromatase inh1b1tors are useful m 
preventing breastcancer. lfofficacy is shown, aromataso inhibitors should be 
compared to the current standards of prevention, raloxifene and tamoxifen. 
Bilateral prophylactic mastectomy 
For patients woo want a higher risk reduction than chemoprevention can 
provide, a bilateral prophylacoc mastectomy {BPM) may te an option. This 
radical, irreversible procedure is mainly reserved for high-nsk women clas-
sified by a mutation of the BRCA t and BRCA2 or a genetic predisposition 
for breast cancer. Several studies on this topic have determined at least a 
90 percent risk reductionP42' Several different types of mastectomies exist, 
with each type removing varying amounts of breast llSsue. However, the nsk 
cannot be completely eliminated tecause 100 percent of the breast IJssue IS 
not removed in the surgeries. Mastectomies removing greater percentages 
of breast tissue are lound to be more effecove.11 While studies show a signifi-
cant risk reducoon in mcdence of breast cancer, mastectomies can also have 
p:;ychosocial effeclS on the patient regarding appearance, sexuality, body im-
age and emobonal ui:set 26 When discussing possible prophylacoc measures 
with paoents, It ts important to weigh the nsks versus oonefits as well as to 
ensure that the patJentclearly understands all aspects of this procedure. 
Conclusion 
In the past few decades, chemoprevention with tamoxifen and raloxifene 
has been used as the therapy of cf-oice in preventing the development of 
breast cancer in hgh-risk patients. The studies have demonstrated similar 
efficacy in the prevention of breast cancer with either SERM treatment 
but, at the same time, noted different adverse event profiles. Addmonal 
therapies, such as aromatase mhibtors, are currently being studied for use 
in h1gh-nsk pallents with possible significance m treatment for the future. 
Recently, mastectomies have gamed attention as another optJon for breast 
cancer prevent!On although they are reserved for the highest-nsk pabenlS 
due to the irreversible nature of this treatment option and its risks. Whether 
or not radical treaoment or chemoth9rapeulic options are better for prevent-
ing breast cancer in high-nsk patients has yet to be seen 1n a single study 
Considering incl1vldual pabents and their risk for breast cancer IS lmJXJrtant 
in deciding which type of preventative treatment patients should receive. As 
women contJnue to become more proactive in breast cancer prevention, It 
is anticipated that an expans10n of preventative therapy will continue. 
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